202.5 Predictors of missing instruments in a postoperative lung cancer cohort Jian Li 1 , Shizhu Li 1 1 Chongqing Medical Univerisity, Chongqing, China Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :202.5 Aims Missing patient-reported outcome (PRO) data can significantly impact the validity of cohort studies
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, with Phase 2 data showing substantial weight reduction over 48 weeks
For fatigue-prone individuals, evening injection is almost always the better choice
This guide covers everything
The PD 5 years subgroup had numerically larger improvements in all three diary states (-1.5, -3.3, and +5.1 hours).[Figure 1] Compared to overall trial results, the incidences of commonly occurring adverse events were (overall, levodopa-only, PD 5 years): hallucinations (21%, 21%, 29%), dizziness (16%, 21%, 21%), dry mouth (16%, 18%, 14%) peripheral edema (15%, 18%, 14%) constipation (13%, 11%, 21%), and fall (13%, 11%, 7%)
At New Body Aesthetics, we have chosen to align with FDA-approved medications to maintain the highest standards of care